Antibody/T-cell receptor chimeric constructs and uses thereof

US10098951B2 · kind B2 · utility

Assignee

• Eureka Therapeutics, Inc. · US

Inventors

• Jingwei Lu · Union City, US
• Zhiyuan Yang · Albany, US
• Cheng Liu · Richmond, US
• Hong Liu · Seattle, US
• Yiyang Xu · Pleasanton, US
• Su Yan · Tangxia, CN
• Vivien Chan · Emeryville, US
• Lucas HORAN · Emeryville, US

Key dates

• Filing date: Dec 1, 2017
• Grant date: Oct 16, 2018
• Expiry date: Dec 1, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application provides antibody-TCR chimeric constructs comprising an antibody moiety that specifically binds to a target antigen fused to a TCRM capable of recruiting at least one TCR-associated signaling module. Also provided are methods of making and using these constructs.